List of Excipients in Branded Drug INDERAL XL

« Back to Dashboard

Company	Tradename	Ingredient	NDC	Excipient	Potential Generic Entry
ANI Pharmaceuticals Inc	INDERAL XL	propranolol hydrochloride	62559-600	DIETHYL PHTHALATE
ANI Pharmaceuticals Inc	INDERAL XL	propranolol hydrochloride	62559-600	ETHYLCELLULOSE
ANI Pharmaceuticals Inc	INDERAL XL	propranolol hydrochloride	62559-600	FD&C BLUE NO. 2
ANI Pharmaceuticals Inc	INDERAL XL	propranolol hydrochloride	62559-600	GELATIN
ANI Pharmaceuticals Inc	INDERAL XL	propranolol hydrochloride	62559-600	HYPROMELLOSE 2910
ANI Pharmaceuticals Inc	INDERAL XL	propranolol hydrochloride	62559-600	HYPROMELLOSE PHTHALATE
ANI Pharmaceuticals Inc	INDERAL XL	propranolol hydrochloride	62559-600	POLYETHYLENE GLYCOL 400

Inderal XL Excipient Strategy and Commercial Opportunities

Last updated: September 26, 2026

Inderal XL is a prolonged-release propranolol hydrochloride product whose commercial value depends more on formulation performance, supply reliability, and differentiated delivery than on active-ingredient exclusivity. The core opportunity is to develop a bioequivalent extended-release capsule with lower manufacturing cost, improved patient acceptability, and regulatory flexibility across markets.

The propranolol molecule is off patent. Generic competition is established, and the main barriers are formulation equivalence, dissolution control, scale-up, regulatory approval, and dependable supply of functional excipients.

What is Inderal XL and how does its formulation work?

Inderal XL is a modified-release oral dosage form containing propranolol hydrochloride. Product naming varies by jurisdiction. Related products are marketed as Inderal LA, Inderal XL, Inderal Retard, or propranolol prolonged-release capsules.

The product is designed to release propranolol over an extended period, generally enabling once-daily administration compared with immediate-release propranolol tablets that may require multiple daily doses. Propranolol has substantial first-pass metabolism and a relatively short elimination half-life, making release-rate control commercially and clinically relevant.

Inderal XL product profile

Attribute	Product characteristic
Active ingredient	Propranolol hydrochloride
Dosage form	Prolonged-release capsule
Common strengths	80 mg and 160 mg, depending on market
Release design	Modified-release multiparticulate or coated-pellet system
Primary indications	Hypertension, angina, arrhythmias, migraine prophylaxis and other propranolol indications, subject to local labeling
Administration	Usually once daily
Regulatory category	Small-molecule prescription drug
Biosimilar exposure	None
Generic exposure	High
Patent position	Legacy molecule and legacy modified-release technology; no broad active-molecule exclusivity

Public product information for prolonged-release propranolol products describes capsule systems using coated particles or pellets. The functional architecture commonly includes a drug-containing core, polymeric release-control coating, anti-tacking agents, and a capsule shell. Exact excipient identity and concentration can vary by manufacturer and jurisdiction. [1][2]

What excipients protect the extended-release performance of Inderal XL?

The commercial formulation objective is not simply to slow dissolution. It is to produce a reproducible in vitro release profile that translates into acceptable pharmacokinetics across fed and fasted conditions.

Core excipient functions

Formulation function	Typical excipient strategy	Commercial purpose
Pellet or core formation	Sugar spheres, microcrystalline cellulose or other inert starter cores	Provides a uniform substrate for drug layering
Drug-layer binding	Hypromellose or comparable film former	Controls adhesion and coating uniformity
Release-rate control	Ethylcellulose or another water-insoluble polymer	Produces sustained diffusion-controlled release
Porosity adjustment	Water-soluble pore former, such as a low-viscosity hydrophilic polymer	Tunes release without changing drug loading
Anti-tacking	Talc or colloidal silicon dioxide	Prevents pellet agglomeration during coating
Film flexibility	Plasticizer, where required	Reduces cracking and mechanical failure
Capsule shell	Gelatin or hypromellose	Encapsulates the multiparticulate fill
Appearance and identification	Titanium dioxide, iron oxides or other approved colorants	Supports product identification and market compliance

A pellet-based design provides several advantages over a single hydrophilic matrix tablet. Individual particles can distribute through the gastrointestinal tract, reducing dependence on tablet geometry and potentially improving release consistency. Multiparticulate systems also offer a route to sprinkle formulations if the pellets maintain their release properties after transfer to soft food.

Which excipient attributes are critical?

The highest-value excipient attributes are particle-size distribution, viscosity consistency, moisture content, coating-grade quality, compressibility where relevant, and regulatory status in the target market.

For ethylcellulose or comparable release polymers, small changes in viscosity, polymer substitution, particle size, or coating dispersion can alter film permeability. Talc and silicon dioxide can affect coating rheology and nozzle performance. Sugar spheres can influence drug-layer uniformity and batch-to-batch pellet size.

A robust control strategy should link:

1. Excipient material attributes.
2. Process parameters for drug layering and coating.
3. Pellet size distribution.
4. Dissolution profile across multiple pH conditions.
5. Pharmacokinetic exposure and peak-to-trough behavior.

The relevant product quality attributes include assay, content uniformity, capsule fill weight, moisture, mechanical integrity, dissolution at multiple time points, and stability under accelerated conditions.

What formulation opportunities exist for Inderal XL generics?

The strongest opportunities are incremental improvements that preserve the once-daily profile while reducing manufacturing or patient-use friction.

Lower-cost multiparticulate manufacturing

A generic manufacturer can evaluate aqueous polymer coating rather than solvent-based coating, provided the process produces equivalent film quality and avoids drug migration, agglomeration, or excessive drying time. Aqueous coating can reduce solvent-handling requirements and improve environmental and occupational controls.

Continuous or semi-continuous coating may improve utilization of production assets. The commercial benefit depends on batch scale, coating yield, and the ability to maintain pellet uniformity.

Sprinkle or capsule-opening presentation

A capsule that can be opened and sprinkled onto soft food could address swallowing difficulties. This strategy is commercially attractive only if the product label permits the practice and the release profile remains unchanged after administration.

The principal risks are:

• Pellets adhering to food or packaging.
• Loss of dose during transfer.
• Chewing or crushing that destroys the release coating.
• Food-induced changes in absorption.
• Need for additional clinical or regulatory evidence.

A "do not chew or crush" warning is common for modified-release products. A deliberately designed sprinkle product could differentiate from conventional generic capsules, but the regulatory package would be more demanding than a standard ANDA or abridged application.

Hypromellose capsule shells

Replacing gelatin with a hypromellose capsule may create a vegetarian, halal, kosher, or temperature-stable product position. The change can affect moisture transfer, shell dissolution, pellet stability, and packaging requirements.

This is a practical line-extension opportunity where local labeling and regulatory rules permit an excipient change. It is more commercially credible than a broad therapeutic repositioning because it targets a visible patient and procurement requirement.

Lactose-free and allergen-controlled versions

A lactose-free formulation can improve institutional procurement flexibility and reduce restrictions in selected patient populations. The value depends on whether lactose is present in the target reference product or competitor products. Excipients should be selected with attention to regional allergen declarations and patient-facing labeling.

Pediatric and liquid alternatives

Propranolol oral solutions and suspensions already occupy pediatric and specialty niches. A new modified-release liquid would face substantial formulation and pharmacokinetic complexity because the release mechanism must remain stable after administration and during storage.

The more practical opportunity is a clearly differentiated immediate-release liquid or an age-appropriate multiparticulate product, rather than attempting to convert Inderal XL directly into a liquid extended-release formulation.

What is the patent and exclusivity position for Inderal XL?

Inderal XL has limited patent-based protection because propranolol is a mature small molecule. The original propranolol composition-of-matter patents expired many years ago. Legacy controlled-release patents would also generally have expired or become commercially irrelevant unless a later manufacturer developed a new, independently claimed delivery system.

Patent and exclusivity assessment

Protection category	Current commercial relevance
Propranolol composition of matter	Expired
Original Inderal brand rights	Trademark and commercial rights only
Legacy extended-release technology	Generally expired or non-blocking
Formulation patents	Relevant only if a later product has an unexpired, enforceable claim
Method-of-use patents	Usually limited value for established propranolol indications
FDA new-drug exclusivity	Not a current barrier to standard generic entry
Biosimilar exclusivity	Not applicable
Orange Book-listed patents	Must be checked by specific reference product and jurisdiction

A generic applicant should not assume that the absence of active ingredient patents eliminates all risk. A later modified-release formulation, capsule technology, manufacturing process, or combination product could have separate claims. The practical freedom-to-operate review should cover U.S. patents, European validations, national filings, litigation records, and formulation patents owned by the reference sponsor or generic competitors.

What is the Orange Book status of Inderal XL?

The FDA Orange Book is relevant only to the U.S. reference product and U.S. listed equivalents. "Inderal XL" is not necessarily the U.S. product name. U.S. propranolol extended-release products have historically been marketed under different names and may appear as discontinued, prescription, or generic entries depending on the product and listing status.

A company pursuing a U.S. product should verify:

• The currently designated reference-listed drug.
• Whether the reference product is active or discontinued.
• Orange Book patent listings.
• Therapeutic equivalence codes for existing generics.
• The applicable ANDA pathway.
• Whether a Paragraph IV certification is required or commercially useful.

For an old, genericized product, a Paragraph IV challenge may have limited strategic value unless a specific unexpired patent remains listed. A standard Paragraph III or "certified" pathway may be more appropriate where patents have expired or are absent. FDA approval and patent clearance remain separate questions. [3]

When did Inderal XL lose exclusivity?

Inderal's underlying market exclusivity ended decades ago. Propranolol has been subject to generic competition for many years, and extended-release propranolol products have also been exposed to generic substitution.

There is no biosimilar risk because propranolol is a chemically synthesized small molecule. The relevant competitive risks are:

• ANDA or national generic approvals.
• Authorized generic supply.
• Hospital and pharmacy tendering.
• Private-label substitution.
• Price erosion.
• Shortages of coating polymers or capsule shells.
• Competitor line extensions with improved presentation.

The timing of a new generic launch is determined less by original Inderal exclusivity than by the applicant's development cycle, regulatory review, patent certification, supply readiness, and local substitution rules.

Which companies are challenging Inderal XL commercially?

The competitive set consists primarily of generic manufacturers rather than named biosimilar developers. The most relevant competitors are companies that can supply propranolol extended-release capsules at scale, maintain stable dissolution performance, and meet local pharmacopoeial and regulatory requirements.

Competition is likely to come from:

• Large multinational generic manufacturers.
• Regional suppliers with established propranolol portfolios.
• Contract development and manufacturing organizations.
• Specialty companies offering pediatric or alternative capsule presentations.
• Authorized or branded-generic suppliers.

Public data generally does not support attributing a specific Paragraph IV challenge to every marketed generic product. Litigation status must be assessed product by product through FDA records, court dockets, and national patent registers. No broad, current litigation barrier should be presumed for the Inderal XL concept without a jurisdiction-specific search. [3][4]

What licensing deals and manufacturing barriers affect Inderal XL?

The most relevant licensing opportunities involve enabling technology rather than the propranolol molecule.

Potential licensing targets

• Multiparticulate coating platforms.
• Modified-release polymer systems.
• Low-solvent or aqueous coating processes.
• Sprinkle-compatible pellet technology.
• Hypromellose capsule technology.
• Continuous manufacturing and in-line dissolution controls.
• Pediatric multiparticulate delivery platforms.

A license is commercially rational where it shortens development time or provides a defensible formulation claim. Licensing an ordinary propranolol generic formulation is less attractive because multiple suppliers can reproduce the product and pricing pressure is high.

Manufacturing barriers

The key manufacturing barriers are process-specific:

• Uniform drug layering across pellet populations.
• Consistent coating weight gain.
• Prevention of pellet agglomeration.
• Control of coating defects and pore formation.
• Stable dissolution after packaging and storage.
• Reliable capsule filling without pellet segregation.
• Qualification of multiple polymer and capsule-shell suppliers.

A dual-source excipient strategy can reduce shortage risk, but switching suppliers may require comparability work and, in some jurisdictions, regulatory notification or approval. Functional equivalence is more important than chemical similarity for release-control excipients.

How strong is the Inderal XL patent estate?

The patent estate is weak as a blocking asset and stronger as a formulation-development opportunity. The molecule itself does not provide meaningful exclusivity. A new entrant would need to create value through:

• Lower cost of goods.
• Better dissolution robustness.
• Improved capsule usability.
• Patient-oriented excipient selection.
• Supply-chain resilience.
• Geographic registration.
• Differentiated packaging or adherence support.

New patents may be available for a specific polymer ratio, pellet architecture, manufacturing sequence, dissolution profile, or sprinkle formulation. Such claims must be drafted around measurable technical parameters rather than broad ownership of prolonged-release propranolol.

How does Inderal XL compare with immediate-release propranolol?

Factor	Inderal XL or LA	Immediate-release propranolol
Dosing frequency	Usually once daily	Often multiple daily doses
Formulation complexity	High	Low to moderate
Generic development cost	Higher	Lower
Excipient dependence	High, especially polymer coating	Lower
Manufacturing risk	Pellet and coating variability	Tablet compression and blend uniformity
Patient convenience	Higher	Lower for frequent dosing
Regulatory differentiation	Modified-release bioequivalence required	Conventional bioequivalence
Patent opportunity	Narrow formulation claims	Limited
Price pressure	High but may support premium niche variants	Very high

The commercial case for Inderal XL remains strongest where once-daily adherence, stable exposure, or patient convenience supports a price or procurement advantage.

What generic launch scenarios exist for Inderal XL?

Three launch models are commercially credible.

Standard generic capsule

This is the lowest-risk strategy. It targets pharmacy substitution and institutional procurement with a conventional prolonged-release capsule. The main requirement is robust bioequivalence and dissolution matching.

Value-added generic

This model uses a gelatin-free shell, lower-allergen excipient profile, improved packaging, or a more reliable supply chain. It may command limited differentiation but can improve tender eligibility.

Specialty multiparticulate product

A sprinkle-compatible, pediatric-oriented, or swallowing-friendly product has greater technical and regulatory risk. It also has better potential for differentiated pricing and formulation patent protection.

Key Takeaways

• Inderal XL is a propranolol hydrochloride prolonged-release product, with market naming varying by jurisdiction.
• The molecule and legacy exclusivity are expired, so commercial protection must come from formulation execution.
• The most important excipients are release-control polymers, film formers, anti-tacking agents, inert cores, capsule-shell materials, and plasticizers where required.
• Generic competition is established, and the primary risks are price erosion, bioequivalence failure, coating variability, and supply disruption.
• The strongest opportunities are aqueous or continuous coating, gelatin-free capsules, sprinkle-compatible pellets, and excipient supply resilience.
• A standard generic has the lowest risk but limited differentiation. A value-added multiparticulate product has greater commercial upside.
• U.S. applicants must assess the current Orange Book reference product, patent listings, therapeutic-equivalence codes, and Paragraph IV requirements.
• Biosimilar risk does not apply. Generic and authorized-generic competition does.
• New patent value is most likely to arise from a specific delivery architecture or manufacturing process, not from propranolol itself.

FAQs

Is Inderal XL the same as Inderal LA?

They generally refer to prolonged-release propranolol products, but the exact formulation, strength, capsule shell, excipients, and regulatory status can vary by market and manufacturer.

Can Inderal XL capsules be opened and sprinkled on food?

Only where the product labeling specifically permits it. Opening or chewing a conventional modified-release capsule can change the release profile and dose delivery.

Which excipient is most important in Inderal XL?

The release-control polymer is usually the most influential excipient because its coating properties determine water penetration, drug diffusion, and the dissolution profile.

Is a new Inderal XL formulation eligible for patent protection?

Potentially, if it has a novel and non-obvious pellet structure, polymer system, manufacturing method, or performance profile. A generic extended-release formulation without a technical distinction is unlikely to provide strong patent protection.

Does Inderal XL have biosimilar competition?

No. Propranolol is a chemically synthesized small molecule. Competition proceeds through generic-drug pathways, not biosimilar regulation.

References

1. Electronic Medicines Compendium. (n.d.). Inderal LA 80 mg prolonged-release capsules: Summary of product characteristics. https://www.medicines.org.uk
2. U.S. National Library of Medicine. (n.d.). DailyMed: Propranolol hydrochloride extended-release capsules. https://dailymed.nlm.nih.gov
3. U.S. Food and Drug Administration. (n.d.). Approved drug products with therapeutic equivalence evaluations, Orange Book. https://www.accessdata.fda.gov/scripts/cder/ob/
4. European Medicines Agency. (n.d.). European public assessment reports and medicines database. https://www.ema.europa.eu